The effect of oxymetazoline nasal spray on the physical capacity in patients suffering from chronic obstructive pulmonary disease

The effect of oxymetazoline nasal spray on the physical capacity in patients suffering from COPD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2020-005013-40-NO

Enrollment

Registered

2021-01-18

Start date

2022-08-30

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease

Interventions

Trade Name: Otrivin Product Name: Otrivin Product Code: R01A A07 Pharmaceutical Form: Nasal spray

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 67 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: other obstructive pulmonary diseases malignancies pregnancy

Design outcomes

Primary

Measure	Time frame
Main Objective: Study if opening the nose improves the physical capacity of patients suffering from COPD;Secondary Objective: Not applicable;Primary end point(s): Walking distance before and after nasal decongesing;Timepoint(s) of evaluation of this end point: when the patients stop walking	—

Secondary

Measure	Time frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable	—

Countries

Norway

Contacts

Public Contactsverre steinsvag

sorlandet Hospital

sverre.steinsvag@sshf.no

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026